Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingAetna Cerebral Perfusion Coverage Update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0663

    Cerebral Perfusion Studies

    Customize your policy alerts

    Sign up for Aetna Policy 0663 alerts

    Get alerted when Policy 0663 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for cerebral CT and MRI perfusion studies, including when they are medically necessary versus considered experimental/investigational, for providers and claim reviewers.

    Policy Summary
    PayerAetna
    PolicyCerebral Perfusion Studies
    Policy CodePolicy 0663
    Change TypeNo material change
    Effective DateMay 2, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain and document clinical justification that CTP is used as a supplement to non-contrast head CT or that MRI is unavailable/contraindicated when ordering CT perfusion.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2modalities discussed (CT, MRI)
    15+experimental/investigational indications listed
    ~88-90%pooled sensitivity for PWI tumor recurrence
    nationalapplicability
    09/14/2023last review

    Coverage Criteria

    inv-01: Medically necessary indications

    Aetna considers the following cerebral perfusion studies medically necessary when ALL listed conditions are met (grouped by modality and indication):

    CT perfusion for acute cerebral ischemia (acute stroke)

    • CT perfusion clinical options: Option A: CT perfusion is used as a supplement to non-contrast head CT; Option B: Magnetic resonance imaging is unavailable or contraindicated
    MRI perfusion for acute cerebral ischemia (acute stroke): Cerebral magnetic resonance imaging perfusion studies (diffusion-weighted or perfusion-weighted) for the evaluation of acute cerebral ischemia.

    inv-02: Experimental / Investigational (Not medically necessary)

    The following indications are considered experimental and investigational because effectiveness has not been established:

    Policy Summary
    PayerAetna
    PolicyCerebral Perfusion Studies
    Policy CodePolicy 0663
    Change TypeNo material change
    Effective DateMay 2, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain and document clinical justification that CTP is used as a supplement to non-contrast head CT or that MRI is unavailable/contraindicated when ordering CT perfusion.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications (Detailed)CodingProvider Actions / Billing GuidancePrior AuthorizationContrast Use and Modality SelectionNot Covered / Investigational IndicationsDefinitions and Technical TermsBackground and Evidence SummaryRevision History
    CT perfusion experimental / investigational indications: Includes but is not limited to: confirmation of brain death; differentiation of lung cancer from benign lesions; evaluation of vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage; evaluation of cerebral gliomas (grading and differentiation from lymphoma, metastasis, and abscess); evaluation of chronic cerebral ischemia; head trauma; herpes simplex encephalitis; monitoring Moyamoya disease; prognosis of traumatic brain injury; prognostic evaluation of cognitive impairment; triaging persons with stroke for thrombolytic therapy; use in the balloon occlusion test; use in vascular neurosurgery.
    MRI perfusion experimental / investigational indications: Includes but is not limited to: assessment of response to angiogenesis inhibitors in glioblastoma; diagnosis of recurrent brain metastases after radiotherapy; differentiation of radiation-induced necrosis from recurrent tumor; evaluation of brain arteriovenous malformations; evaluation of head and neck cancers; evaluation of glioma recurrence vs pseudo-progression; differentiation of high-grade glioma from primary CNS lymphoma; evaluation of low-grade vs high-grade gliomas; evaluation of idiopathic normal pressure hydrocephalus; evaluation of pediatric post-operative cerebellar mutism syndrome; evaluation of persistent pain; evaluation of traumatic brain injury; assessment of tumor progression after glioma radiotherapy; identification of new infarcts following ischemic injury; prognostication of obstructive sleep apnea; use as a biomarker for Parkinson's disease.

    inv-03: Clinical indications supported by cited evidence

    Evidence-supported clinical uses and supporting findings (study-level):

    Acute ischemic stroke (core vs penumbra): CTP may differentiate infarct core from ischemic penumbra and, when MRI is unavailable, provide useful information for acute stroke evaluation; multimodal CT (NCCT+CTP+CTA) may aid diagnosis and treatment decision-making.

    Supported by Wang et al (2010) and guideline summaries; multimodal CT described as useful when MRI unavailable (chunks 18, 22).

    Unknown-onset stroke thrombolysis (feasibility research): Pilot randomized PCT-guided thrombolysis trials are feasible but face operational challenges (treatment delays, reliable tissue-at-risk identification); safety and efficacy remain to be established.

    Michel et al (2012) pilot randomized feasibility study (chunk 21).

    Delayed cerebral ischemia (DCI) after aneurysmal SAH: CTP shows diagnostic value for DCI in the 4–14 day window with pooled sensitivity and specificity in systematic reviews (approximate pooled sensitivity ~0.84, specificity ~0.77); perfusion parameter changes (decreased CBF, increased MTT) are associated with DCI but thresholds need standardization.relative CBF threshold reported in some studies (~0.9)

    Cremers 2014, Mir 2014, meta-analyses (chunks 25, 26, 33).

    Low-dose volume perfusion CT for vasospasm detection: Low-dose VP CT protocols may preserve diagnostic accuracy for detecting perfusion impairment related to vasospasm after SAH, with reported high sensitivity and specificity in a retrospective study.tube current-time product 72 mAs simulated vs 180 mAs original

    Afat et al (2018) retrospective study reported sensitivity 99.0% and specificity 99.5% (chunk 29).

    Prediction of hemorrhagic transformation and prognosis in AIS: CTP-derived measures (core/penumbra volumes, BBB permeability metrics) have been associated with prediction of hemorrhagic transformation and functional outcome; pooled sensitivity and specificity reported in meta-analysis (pooled sensitivity ~86%, specificity ~74%).

    Adebayo & Culpan (2020) systematic review and related prognostic reviews (chunks 51, 54).

    Prognosis after severe traumatic brain injury: Early CTP performed at first follow-up NCCT provided prognostic information with high predictive accuracy (abnormal CTP AUC = 0.92) in a prospective observational study.

    Bendinelli et al (2017) prospective study (chunk 36).

    Selection for endovascular therapy (target mismatch): CTP classification of 'target mismatch' (small core, large penumbra) was associated with higher odds of favorable response to reperfusion and supports patient selection up to extended time windows in cohort studies (CRISP/DEFUSE-related evidence).

    Lansberg et al (CRISP) multicenter cohort findings (chunk 38).

    inv-04: Descriptive coverage-relevant evidence summaries

    Clinical situations where CTP has supporting evidence:

    Severe traumatic brain injury prognostication: CTP performed with the first follow-up NCCT after severe TBI provided additional prognostic information and showed high discrimination for unfavorable 6‑month outcome in a prospective series (AUC abnormal CTP = 0.92).

    Single-center observational study; larger studies recommended (chunk 36).

    Selection for endovascular therapy in ischemic stroke: CTP target-mismatch patterns (small core, large penumbra) were associated with greater odds of favorable response to reperfusion, providing cohort evidence to support CTP use for extended-window selection in research and practice contexts.

    CRISP multicenter cohort (chunk 38) with limitations including lack of randomized control group.

    Prediction of hemorrhagic transformation in AIS: Meta-analyses and cohort studies report that CTP-derived measures can stratify risk of hemorrhagic transformation with reasonable sensitivity and moderate specificity, though heterogeneity limits precise thresholds and performance estimates.

    Adebayo & Culpan (2020) and related systematic reviews (chunk 51).

    inv-05: Evidence summaries with coverage implications

    Evidence-based statements and performance estimates from systematic reviews/meta-analyses

    Differentiation of high-grade glioma (HGG) from primary CNS lymphoma (PCNSL): Perfusion MRI (PWI) shows high diagnostic accuracy for distinguishing HGG from PCNSL (pooled AUC ~0.94); DSC may have the highest sensitivity and ASL higher specificity, but variability in optimal thresholds and methodology limit routine universal adoption without standardization.AUC values reported

    Xu et al (2017) and Suh et al (2019) meta-analyses (chunks 91, 93).

    Differentiation of low-grade glioma (LGG) from high-grade glioma (HGG): DSC-derived rCBV with a commonly used cutoff (rCBV < 1.75) yields moderate sensitivity but variable and often low specificity; limited sample sizes and heterogeneity reduce reliability.rCBV < 1.75

    Meta-analysis pooled estimates and limitations (chunk 96).

    Diagnosis of recurrent brain metastases after radiotherapy: DSC MR perfusion demonstrates pooled sensitivity ~81.6% and specificity ~80.6% for discriminating recurrence from treatment-related change, but substantial heterogeneity and methodological limitations warrant cautious interpretation.pooled SENS/SPEC values

    Kwee & Kwee (2020) meta-analysis (chunk 99).

    Evaluation of tumor progression after glioma radiotherapy: DSC-PWI shows pooled sensitivity and specificity around 0.83 for detecting tumor progression versus treatment effect; DCE and ASL show moderate accuracy with fewer studies; overall evidence moderate and influenced by heterogeneity.pooled SENS/SPEC values

    Meta-analysis of 20 studies (chunk 102).

    Pediatric post‑operative cerebellar mutism syndrome (ppCMS): ASL, DSC and SPECT studies suggest frontal hypoperfusion associated with ppCMS; evidence is limited (small studies) and preoperative imaging is generally lacking, so findings are hypothesis‑generating and require prospective validation.association only

    Systematic review (Ahmadian et al 2021) (chunk 104).

    Examples of ICD-10 diagnoses referenced in the policy as not covered for the investigational indications include: B00.4 (Herpesviral encephalitis), C71.0–C71.9 (Malignant neoplasm of brain; glioma), G93.82 (Brain death), G31.84 (Mild cognitive impairment), and G20 (Parkinson's disease). These codes appear in the document lists of diagnoses for which perfusion imaging is identified in the investigational/not-covered context.

    Use of cerebral CT or MRI perfusion studies for the indications listed in the policy’s Experimental/Investigational section is considered not medically necessary because effectiveness has not been established. The policy explicitly states that cerebral CT perfusion and cerebral MRI perfusion studies are not medically necessary for the many investigational indications enumerated (see policy lists), and claims for those indications may be denied when billed for those diagnoses.

    CT and MRI perfusion are identified as not covered for a range of investigational indications. Examples include perfusion imaging for confirmation of brain death, evaluation and grading of cerebral gliomas (including differentiation from lymphoma, metastases, and abscess), assessment of response to angiogenesis inhibitors in glioblastoma, diagnosis of recurrent brain metastases after radiotherapy, and evaluation of moyamoya, traumatic brain injury, cognitive impairment, idiopathic normal pressure hydrocephalus, and Parkinson’s disease biomarker use. The policy states these uses are experimental/investigational because effectiveness has not been established and are considered not medically necessary.

    Covered Indications (Detailed)

    inv-77: Acute cerebral ischemia (acute stroke)

    Acute cerebral ischemia (acute stroke): top-level coverage node

    Acute cerebral ischemia (acute stroke): Use CTP or MR perfusion to evaluate suspected acute cerebral ischemia when criteria for modality-specific medical necessity are met (see modality nodes).

    inv-78: Appropriate clinical indications and supporting evidence for cerebral CTP

    Appropriate clinical indications and supporting evidence for cerebral CTP — summarized top-level items

    Acute ischemic stroke evaluation: CTP as part of multimodal CT (NCCT + CTA + CTP) to assess infarct core vs penumbra when MRI is unavailable or contraindicated; may inform thrombolysis/endovascular decisions.
    Delayed cerebral ischemia (DCI) after SAH: CTP can detect perfusion deficits indicative of DCI in the 4–14 day window; pooled sensitivity/specificity moderate and thresholds require standardization.
    Intra‑operative vascular neurosurgery: Intra‑operative CTA and CTP are feasible and can impact intra‑operative decision making in small pilot series.
    Low‑dose VP CT for vasospasm detection: Low‑dose volume perfusion CT protocols may maintain diagnostic accuracy for detecting vasospasm-related perfusion impairment compared with original dose protocols.
    Prognosis after severe TBI: Early CTP performed at first follow‑up NCCT may provide prognostic information for functional outcome at 6 months.
    Prediction of hemorrhagic transformation: CTP-derived biomarkers (core/penumbra volumes, BBBP) associated with prediction of hemorrhagic transformation with reasonable sensitivity and moderate specificity in pooled analyses.

    inv-79: Indications supported by evidence summaries in document

    Indications supported by evidence summaries in the document:

    Severe TBI prognostication: Early CTP adds prognostic information beyond NCCT and clinical scores; single prospective study reported high AUC but calls for larger validation studies.
    Selection for endovascular therapy: CTP target‑mismatch supports selection for reperfusion therapies and is associated with favorable treatment response in cohort data, informing extended‑window selection strategies.
    Prediction of hemorrhagic transformation and outcomes: CTP measures correlate with HT risk and outcomes in AIS; meta-analyses report pooled sensitivity and specificity but highlight methodological heterogeneity.

    inv-80: Clinical and research indications described in evidence summaries

    Clinical and research indications described in evidence summaries:

    Assorted clinical and research uses: Includes prognostication and selection for reperfusion in acute stroke, posterior circulation stroke evaluation, limited utility for lacunar (RSSI) infarcts due to false negatives, prognostic evaluation in cognitive impairment using FDG‑PET/SPECT/MRI, tumor perfusion for response assessment, evaluation of iNPH and shunt response, and research applications (e.g., ASL for pediatric AVM, pain studies).

    inv-81: Selected clinical uses of cerebral perfusion MRI

    Selected clinical uses of cerebral perfusion MRI summarized from evidence:

    iNPH and shunt response: DSC MRI demonstrated pre‑operative reduced rCBF correlated with symptoms and predicted shunt outcome in small studies; post‑operative rCBF increases correlated with clinical improvement.
    Differentiation of recurrent tumor vs treatment effect: Perfusion MRI (DSC/DCE/ASL) improves diagnostic performance for distinguishing recurrence from radiation necrosis or pseudo‑progression with pooled sensitivities and specificities in meta‑analyses, though thresholds vary.
    Tumor response assessment to anti‑angiogenic therapy: Parametric response maps of rCBV changes correlated with PFS and OS in recurrent glioblastoma cohorts, suggesting potential early markers of response.
    Differentiation of HGG from PCNSL: PWI techniques (DSC/ASL) show high accuracy for discriminating HGG from PCNSL in pooled analyses, but standardization required before broad clinical adoption.

    inv-82: Appropriate uses with evidence caveats

    Appropriate uses with evidence caveats — items with caveats and conditional interpretation:

    High diagnostic accuracy but variable thresholds: Although pooled AUCs and pooled SENS/SPEC are favorable for several MRI perfusion indications (e.g., HGG vs PCNSL, recurrence vs necrosis), variability in optimal thresholds, acquisition and post‑processing methods limit direct transferability across centers and warrant cautious interpretation.
    Limited evidence for LGG vs HGG grading: rCBV cutoffs (e.g., rCBV < 1.75) show moderate sensitivity but wide specificity ranges and limited sample sizes; standardized scanning and molecular‑aware reference standards are needed.rCBV < 1.75
    Heterogeneity in recurrent metastases studies: Pooled sensitivity and specificity for DSC in distinguishing recurrence from radiation effect are moderate (~81.6% and ~80.6%) with significant heterogeneity and methodologic limitations, limiting definitive clinical thresholds.

    inv-83: CT and MR perfusion imaging indications summarized from cited literature

    CT and MR perfusion imaging indications summarized from cited literature:

    Literature‑supported indications summary: References discuss indications including acute ischemic stroke evaluation (core/penumbra and triage for reperfusion), prediction of hemorrhagic transformation, detection of DCI after SAH, assessment after TBI, tumor grading and recurrence differentiation, pediatric ppCMS evaluation, and other cerebrovascular and neuro‑oncologic applications.

    Coding

    Covered CPT Codes (when selection criteria met)CPTCovered
    0042TCerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time.
    Other related CPT/CT codesCPT
    37195Thrombolysis, cerebral, by intravenous infusion.
    61623Endovascular temporary balloon arterial occlusion, head or neck (extracranial/intracranial) including selective catheterization of vessel to be occluded, positioning and inflation of occlusion balloon, concomitant neurological monitoring, and radiologic supervision and interpretation of all angiography required for balloon occlusion and to exclude vascular injury post occlusion.
    70450CT, head or brain; without contrast material.
    70460CT, head or brain; with contrast material.
    70470CT, head or brain; without and with contrast material.
    70496Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image post-processing.
    Other HCPCS codes related to CPBHCPCS
    C9257Injection, bevacizumab, 0.25 mg.
    J9035Injection, bevacizumab, 10 mg.
    ICD-10 codes covered if criteria are metICD-10Covered
    I63.00 - I63.9Cerebral infarction.
    I65.01 - I65.9Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction.
    I66.01 - I66.9Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction.
    ICD-10 codes not covered for listed CPB indications (examples)ICD-10Not Covered
    B00.4Herpesviral encephalitis.
    C71.0 - C71.9Malignant neoplasm of brain (glioma).
    G93.82Brain death.
    G31.84Mild cognitive impairment, so stated.
    G20Parkinson's disease.
    Covered/Referenced Codesmixed
    No codes listed
    inv-25: relative CBF threshold for DCI prediction (CTP)
    Relative CBF threshold (DCI prediction)0.9
    Reported sensitivity97%
    Reported specificity89%
    inv-26: nCBV and nCBF cut-offs for tumor grading
    nCBV cutoff (tumor grading)> 3.07
    nCBF cutoff (tumor grading)> 2.08
    ContextDistinguishes high-grade gliomas from low-grade gliomas in the cited prospective study
    inv-27: other tumor perfusion cut-offs
    nCBV < 3.40 & nMTT > 1.83Suggests lymphoma vs high‑grade glioma
    nCBV > 4.95 & nMTT > 1.88Suggests metastasis vs high‑grade glioma
    Study limitationsLimited slice coverage and small sample sizes may affect generalizability
    inv-28: rCBV thresholds reported in studies (mean and max ranges)
    Mean rCBV threshold range (studies)0.9 to 2.15
    Maximum rCBV threshold range (studies)1.49 to 3.1
    Use noteReported thresholds show substantial variability across studies and require standardization
    inv-29: rCBV threshold (example pooled cutoff <1.75)
    Pooled rCBV cutoff (LGG vs HGG)rCBV < 1.75
    Performance noteUsing rCBV <1.75 yielded pooled sensitivity ~0.83 and specificity ~0.48 (wide CIs) in pooled analysis
    Evidence caveatLimited sample size and heterogeneity limit reliability

    Provider Actions / Billing Guidance

    Prior Authorization

    Prior Authorization / Administrative Authorization Not Specified

    Prior authorization not specified in this section. The policy text does not state a formal prior authorization (PA) requirement for cerebral CT or MR perfusion studies; there is no explicit administrative authorization or step-therapy described in these excerpts. Providers should verify member benefits and any PA requirements with the payer before performing non-emergent studies.

    • No prior authorization language present in provided excerpts
    • No step therapy requirements described
    Prior Authorization

    Consider PA for Extended‑Window or Nonstandard CTP Use

    Consider prior authorization when CTP is used outside standard indications or time windows (for example, selection for endovascular therapy beyond conventional windows or other nonstandard/extended-window uses). Because evidence and methods are heterogeneous and evolving, additional review may be required and PA can help ensure the indication, protocol, and processing meet clinical criteria before approval.

    • Recommended: obtain PA for extended-window or nonstandard CT perfusion use (e.g., selection for endovascular therapy beyond usual windows)
    • PA especially prudent when institutional protocols or thresholds are not standardized
    Documentation Required

    Prior Authorization: Ensure Indication and Protocol Documentation

    When prior authorization is required (per payer or plan-specific rules), documentation should explicitly include clinical indication and the imaging protocol. Required elements include indication for the perfusion study, time from symptom onset (or rationale if time unknown), relevant clinical scores (eg, NIHSS), results of non-contrast CT or MRI when available, and whether MRI is unavailable or contraindicated when CT is used as a substitute.

    • Document indication and reason CTP is being used (supplement to NCCT or MRI unavailable/contraindicated)
    • Include time window or justification for extended-window use
    • Include relevant clinical severity scores (eg, NIHSS)
    Documentation Required

    Required Documentation Elements

    Required clinical and imaging documentation should include indication, time window, clinical severity scores (eg, NIHSS), core/penumbra estimates, imaging modality used, and processing details. Processing outputs from automated perfusion software (eg, RAPID or equivalent) should be saved and available to support interpretation and utilization for treatment decisions.

    • Indication and time since symptom onset
    • Clinical scores (eg, NIHSS) and pertinent exam findings
    • Non-contrast CT/CTA or MRI findings if available
    • CTP/MRP processed outputs and maps (eg, CBF, CBV, MTT, Tmax)
    Documentation Required

    Processing Documentation

    Processing documentation: automated perfusion-processing outputs and mismatch metrics (eg, core and penumbra volumes, Tmax thresholds, rCBV values) should be recorded and retained in the medical record. When automated software is used, include the software name/version and the quantitative outputs used to make treatment decisions.

    • Record software name and version (eg, RAPID)
    • Save parametric maps and numeric outputs (CBF, CBV, MTT, Tmax)
    • Report core and penumbra volumes and thresholds used
    Documentation Required

    Record Perfusion Metric and Threshold

    Record perfusion metrics and thresholds used in studies and clinical decision-making. Reported thresholds in the literature vary (for example, rCBV thresholds for tumor vs necrosis or rCBV ranges reported in meta-analyses). If thresholds are used to guide therapy, specify the metric (eg, rCBV, Tmax, CBF) and the numeric threshold applied.

    • Specify metric(s) used (eg, rCBV, CBF, Tmax) and numeric thresholds
    • Include threshold ranges where relevant (eg, rCBV ranges reported in studies)
    Denial Risk

    Evidence Limitations May Trigger Additional Review / Non‑standardized Methods Risk Denial

    Evidence limitations and non-standardized methods may trigger additional review or denial. The literature shows heterogeneity in acquisition, post-processing, and reported thresholds; such variability and risk of bias can prompt case-by-case review and denial if prespecified thresholds or standardized methods are not documented.

    • Heterogeneity of methods and thresholds increases likelihood of additional review
    • Lack of prespecified thresholds or standardized processing may prompt denial
    Note

    Limitations and Cost‑Effectiveness Considerations

    Limitations of CTP should be noted in documentation. CTP is unreliable for lacunar (small subcortical) infarcts and should not be relied on alone in that context. For transient ischemic attack (TIA) workups, routine MR DWI is not always cost‑effective; include consideration of cost‑effectiveness and appropriateness of MR versus CT in the record when pertinent.

    • CTP has limited sensitivity for lacunar/RSSI infarcts — avoid sole reliance on CTP for these diagnoses
    • MR DWI is not universally cost‑effective for TIA; consider timing and clinical context
    Note

    Administrative Notes / Not‑Applicable Items

    Not applicable / None specified: In the provided document excerpts there are no explicit step‑therapy requirements, no explicit administrative authorization workflow, and no preoperative-specific authorization steps described. For use in preoperative evaluation or other unlisted indications, obtain prior benefit verification and document clinical rationale; these indications may be considered investigational and risk denial.

    • No step therapy requirements described in provided text
    • No explicit administrative authorization or preoperative authorization instructions in excerpts
    • Investigational indications listed in policy risk denial if used outside listed medically necessary criteria

    Prior Authorization

    Billing Rule

    CT perfusion (0042T) and related CT/CTA claims must meet medical necessity; PA may apply

    Claims for CT perfusion (CPT 0042T) and associated CT/CTA procedures must meet the medical necessity criteria for acute cerebral ischemia to be payable; prior authorization may be required per payer rules.

    • Ensure documentation aligns with medical necessity criteria for acute stroke (supplement to NCCT or MRI not available/contraindicated)
    Prior Authorization

    Consider PA for CT perfusion used outside established workflows (e.g., extended‑window EVT selection)

    Consider prior authorization for CT perfusion when use is outside established workflows — for example, selecting patients for endovascular therapy in extended time windows — due to cohort‑based evidence and potential generalizability limits.

    • Extended‑window EVT selection is an example where PA consideration is reasonable
    Prior Authorization

    Consider PA for DSC/DCE/ASL if protocol or indication is non‑standard

    For DSC, DCE, or ASL MR perfusion studies, prior authorization may be appropriate when documentation does not describe a standardized protocol or when the indication is outside commonly accepted uses due to variable evidence.

    • If using DSC/DCE/ASL for investigational indications or without documented acquisition/post‑processing standards, obtain prior authorization
    Note

    Additional PA notes (none specified in excerpt)

    No additional prior authorization notes are specified in the provided excerpt; follow payer‑specific PA processes where applicable.

    Contrast Use and Modality Selection

    Billing Rule

    CT perfusion requires IV iodinated contrast for dynamic acquisition and post‑processing

    CT perfusion requires intravenous administration of iodinated contrast for dynamic acquisition and post‑processing to derive perfusion parameters—document contrast use in reports and claims.

    • Contrast agent administration is integral to CTP acquisition and should be documented
    Billing Rule

    CTA/CTP for brain death ancillary testing require iodinated contrast and variable protocols

    When CTA/CTP are used as ancillary tests for brain death confirmation, note that iodinated contrast is required and protocols and sensitivities vary across institutions; document the protocol used.

    • CTA/CTP are more invasive than MRA because of contrast injection; sensitivity in studies has been variable
    Billing Rule

    DSC MR perfusion requires contrast bolus and deconvolution processing (document methods)

    DSC MR perfusion uses a contrast bolus and deconvolution algorithms to derive CBV, CBF, and MTT; document contrast administration and post‑processing methods when billing or requesting prior authorization.

    • Document the processing approach (deconvolution, AIF selection) and software if relevant
    Billing Rule

    Use ASL when contrast is contraindicated or in pediatric cases; document rationale

    If contrast is contraindicated or in pediatric patients, ASL (a non‑contrast MR technique) may be used to quantify CBF; document the rationale for choosing ASL over contrast techniques.

    • ASL is appropriate when gadolinium/iodinated contrast is contraindicated or to avoid contrast in children
    Billing Rule

    Choose DSC/DCE/ASL based on diagnostic question and contrast safety; document selection

    Select DSC vs DCE vs ASL based on the diagnostic question and patient factors; document choice of modality and contrast safety considerations in the record.

    • Provide acquisition parameters and post‑processing details to support interpretation and potential coverage review
    Documentation Required

    Document pediatric ASL acquisition parameters and known limitations (arterial transit time, blood T1)

    In pediatric ASL and CBF quantification, be aware that arterial transit time and assumptions about blood T1 can affect measurements; document relevant acquisition parameters (e.g., PLD) and limitations when reporting CBF values.

    • Note potential sensitivity to arterial transit time and T1 of blood especially in pediatric populations

    Not Covered / Investigational Indications

    The policy lists many additional investigational indications for which CT and MR perfusion are not covered, including but not limited to: evaluation of head and neck cancers, monitoring tumor progression after glioma radiotherapy, differentiation of radiation necrosis from recurrent tumor or pseudo‑progression, evaluation of brain arteriovenous malformations, identification of new infarcts after TIA or minor stroke, and pediatric post‑operative cerebellar mutism syndrome. These indications are included in the policy’s Experimental/Investigational lists and thus are considered not medically necessary.

    CT perfusion should not be relied upon as the sole diagnostic test for lacunar (recent small subcortical) infarcts. A systematic review found wide heterogeneity in CTP techniques and low sensitivity for lacunar infarcts (reported sensitivity range 0% to 62.5%), and the authors concluded that CT perfusion cannot reliably diagnose lacunar stroke due to consistent false negative rates; CTP may at best be supportive when a perfusion deficit is seen but is insufficient alone for diagnosis.

    Additional investigational exclusions and cautionary notes include: evidence limitations from study heterogeneity, small sample sizes, variable patient populations, and lack of standardized acquisition and post‑processing protocols; the policy emphasizes that non‑standardized methods and lack of prespecified diagnostic thresholds limit generalizability and may lead to denial for investigational uses. The policy also notes decision analyses questioning whether imaging to select patients for some therapies (e.g., induced‑hypertension for suspected DCI) improves outcomes versus treating all patients, reinforcing that such uses remain investigational.

    Definitions and Technical Terms

    inv-63: CT perfusion (CTP) — definition and outputs
    DefinitionSequential CT acquisition during intravenous iodinated contrast administration with post-processing to calculate regional CBF, CBV, and MTT.
    Primary outputsRegional cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT)
    Clinical useUsed to assess tissue perfusion and help distinguish infarct core from ischemic penumbra in acute stroke evaluation
    inv-64: Penumbra vs. infarct core — definition and relevance
    Penumbra vs infarct core — definitionPenumbra: potentially salvageable ischemic tissue; Infarct core: irreversibly damaged tissue.
    RelevanceDistinguishing core from penumbra informs thrombolytic/reperfusion treatment decisions when MRI is unavailable
    Imaging roleMultimodal CT (NCCT+CTA+CTP) can identify a small core/large penumbra 'target mismatch' for therapy selection
    inv-65: Perfusion parameters — CBF, CBV, MTT, Tmax and related metrics
    CBF (cerebral blood flow)Volume of blood delivered per unit brain tissue per time; key metric for identifying ischemic core and penumbra.
    CBV (cerebral blood volume)Blood volume within cerebral vasculature; used with CBF/MTT to assess tissue viability.
    MTT (mean transit time)Average time for blood to traverse the capillary network; prolonged MTT suggests hypoperfusion.
    Tmax / time-to-peak (TTP)Timing-based surrogates of delayed arrival used in mismatch assessment and automated maps (e.g., RAPID).
    inv-66: ASPECTS — Alberta Stroke Program Early CT Score definition
    ASPECTS — definitionAlberta Stroke Program Early CT Score: a 10‑point quantitative score to assess early ischemic changes on CT imaging.
    UseApplied to evaluate extent of early ischemia and guide acute stroke management decisions.
    ScoringLower scores indicate more extensive ischemic change; used alongside perfusion imaging in some protocols.
    inv-67: Target mismatch — definition used for selection of reperfusion therapy
    Target mismatch — definitionA CTP pattern with a small ischemic core and large penumbra indicating tissue potentially salvageable by reperfusion therapy.
    Clinical useUsed to select patients likely to benefit from endovascular reperfusion, including extended time windows in cohort studies.
    Evidence noteAssociation with favorable response to reperfusion observed in multicenter cohorts (e.g., CRISP); trials used similar concepts (DEFUSE 3).
    inv-68: Blood-brain barrier permeability (BBBP) — CTP-derived estimate definition
    BBBP — definitionCTP-derived estimate of blood–brain barrier permeability used to assess disruption and studied as a predictor of hemorrhagic transformation.
    DerivationEstimated using non-linear regression analysis on perfusion data to quantify permeability metrics.
    Clinical relevanceHas been associated with increased odds of hemorrhagic transformation but may not independently improve predictive AUC over clinical predictors alone.
    inv-69: Diffusion–perfusion mismatch — definition and clinical use
    Diffusion–perfusion mismatch — definitionAn imaging pattern where perfusion deficit (PWI/CTP) exceeds diffusion-restricted lesion (DWI/ADC), indicating potentially salvageable penumbra.
    Clinical useUsed to identify candidates for reperfusion therapy when combined with clinical assessment and automated processing (e.g., RAPID).
    ProcessingAutomated tools compute core and perfusion lesion volumes to quantify mismatch for rapid decision-making.
    inv-70: RAPID — automated processing system that generates perfusion maps
    RAPID — definitionAn automated processing system that generates quantitative perfusion maps (CBV, CBF, MTT, Tmax) and identifies diffusion/perfusion mismatch rapidly.
    PerformanceIn validation, RAPID showed high correlation with human readers and fast processing (mismatch sensitivity 100%, specificity 91% in one evaluation).
    Clinical roleFacilitates expedited routine clinical assessment and trial workflows for acute stroke.
    inv-71: rCBV / rCBF — perfusion MRI-derived metric definitions
    rCBV / rCBF — definitionRelative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF) are perfusion MRI–derived metrics normalized to reference tissue and used to distinguish viable tumor from treatment-related change.
    UsesApplied in tumor grading, differentiation of recurrence vs radiation necrosis, and other neuro‑oncologic assessments.
    Metric variabilityReported optimal thresholds vary across studies; standardization of acquisition and post‑processing is needed for generalizability.
    inv-72: ASL — arterial spin labeling definition (non-contrast MRI perfusion)
    ASL — definitionArterial spin labeling: a non‑contrast MRI technique that quantifies cerebral blood flow by magnetically labeling inflowing blood.
    IndicationsUseful when gadolinium/iodinated contrast is contraindicated and in pediatric/pregnant populations; increasingly used for ischemic stroke and AVM assessment.
    LimitationsCBF quantification can be sensitive to arterial transit time and blood T1 assumptions, especially in pediatric populations.
    inv-73: DCE / DSC — dynamic contrast-enhanced and dynamic susceptibility contrast MRI definitions
    DCE / DSC — definitionDynamic contrast‑enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI are contrast‑based perfusion techniques; DSC commonly provides rCBV, while DCE yields pharmacokinetic permeability measures.
    RequirementsBoth techniques require contrast administration and standardized acquisition/post‑processing for reliable quantitative results.
    Clinical rolesUsed in tumor grading, differentiation of recurrence vs radiation effect, and other perfusion‑based assessments.
    inv-74: rCBV cutoff used to differentiate LGG from HGG in pooled analyses (rCBV < 1.75)
    Pooled rCBV cutoff (LGG vs HGG)rCBV < 1.75
    InterpretationCommonly used cutoff in pooled analyses but associated with variable specificity and limited by small sample sizes and heterogeneity
    RecommendationThresholds require standardization and larger studies before routine cross‑institutional implementation
    inv-75: Perfusion MRI techniques listed (DSC, DCE, ASL)
    Perfusion MRI techniques listedDSC, DCE, ASL
    Technique notesDSC commonly provides rCBV; DCE provides permeability metrics; ASL is non‑contrast CBF quantification.
    Clinical implicationSelection depends on diagnostic question, contrast contraindications, and need for standardized protocols.
    inv-76: DTC tract referenced in pediatric postoperative cerebellar mutism syndrome discussion
    DTC tract — definition/contextDentato‑thalamo‑cortical (DTC) tract referenced as a pathway potentially implicated in pediatric post‑operative cerebellar mutism syndrome; tractography was not available in the cited study.
    Study noteAuthors noted DTC damage was not directly measured and prospective tractography studies are underway to clarify the link.
    Methodological caveatCBF measures may be sensitive to arterial transit time and blood T1 assumptions, which can partially affect findings in pediatric populations.

    Background and Evidence Summary

    Computed tomography perfusion (CTP) acquires sequential CT images during intravenous iodinated contrast administration and, with post‑processing, generates quantitative perfusion maps such as cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT). These derived parameters are used clinically to help distinguish ischemic core from salvageable penumbra in acute ischemic stroke pathways when MRI is unavailable, and to provide rapid, widely available perfusion information to support acute treatment decisions.

    inv-03 (supporting evidence): Clinical indications supported by cited evidence

    Supporting evidence for clinical indications — grouped evidence nodes:

    Acute ischemic stroke: core/penumbra assessment: CTP differentiates infarct core from penumbra and is used when MRI is unavailable; multimodal CT may assist in thrombolysis decisions.
    Delayed cerebral ischemia (DCI) after SAH: Systematic reviews/meta‑analyses report moderate pooled SENS/SPEC for CTP in DCI diagnosis during the 4–14 day window; standardization of perfusion thresholds is needed.
    Prognosis after severe TBI: Prospective observational data indicate early CTP predicts unfavorable 6‑month outcome with high AUC, suggesting prognostic utility pending larger validation studies.

    inv-04: Descriptive coverage-relevant evidence summaries

    Descriptive evidence summaries for coverage-relevant clinical situations:

    Severe TBI prognostic evidence: Single prospective series found abnormal early CTP strongly predictive of unfavorable 6‑month outcome (AUC = 0.92), suggesting potential to inform prognosis and management pending larger studies.
    CTP for endovascular therapy selection: Cohort data (CRISP and related studies) show favorable outcomes among patients with CTP target‑mismatch undergoing reperfusion, supporting use for patient selection in extended windows with recognition of selection bias limitations.
    CTP to predict hemorrhagic transformation: Systematic reviews/meta‑analyses report pooled sensitivity and specificity indicating reasonable predictive performance for HT, though heterogeneity and processing differences affect estimates.
    Limitations: lacunar/RSSI detection: Systematic review indicates CTP has inconsistent sensitivity for recent small subcortical infarcts (lacunar stroke) with frequent false negatives; CTP should not be solely relied upon for RSSI diagnosis.

    The evidence base for many perfusion applications is limited by substantial heterogeneity in study designs, small sample sizes, variable reference standards, and risk of bias. Systematic reviews have highlighted inconsistent patient selection, differences in acquisition and post‑processing methods, and lack of prespecified diagnostic thresholds, all of which reduce confidence in pooled diagnostic accuracy estimates and limit generalizability of reported thresholds and automated software outputs.

    CTP has specific limitations for lacunar (recent small subcortical) infarcts: studies show heterogeneous perfusion patterns and consistently low sensitivity, leading authors to conclude that CT perfusion is unreliable for diagnosing lacunar stroke. Because false negative rates are substantial, reliance on CTP alone may miss recent small subcortical infarcts; larger, prospective, technically homogeneous studies are needed to clarify any role for perfusion imaging in this condition.

    Revision History

    2023-09-14policy reviewLatest

    Policy underwent routine review (Last review recorded).

    2003-05-02effective date

    Policy originally became effective.

    2024-07-25next scheduled review

    Next scheduled policy review date.

    Pediatric ppCMS evidence limited:
    Associations of frontal hypoperfusion with pediatric post‑operative cerebellar mutism syndrome are based on small studies and lack preoperative imaging; use is hypothesis‑generating and primarily research‑oriented at present.